The Australian MND Guideline
The Australian Motor Neurone Disease (MND) Guideline aims to put people with lived experience of MND at the core. Developing these clinical guidelines for MND can help to improve the management and outcomes of up to 2,000 Australians living with MND.
Purpose & Aim of the Australian MND Guideline
The Australian MND Guideline aims to create an evidence-based guideline to improve the care and quality of life for people living with MND.
This important initiative will provide healthcare professionals, caregivers, and policymakers with actionable recommendations to guide MND management across Australia.
The guideline will be supplemented with companion documents that will be developed alongside the formal guideline. The purpose of the companion documents are to help make the MND Guideline actionable and practical in its application to improve outcomes for people living with MND.
Development Approach
Key features of our approach include:
- Community-led and driven by individuals living with MND, caregivers, and healthcare professionals.
- Rigorous methods using GRADE (Grading of Recommendations Assessment, Development, and Evaluation) and following the Australian National Health and Medical Research Council (NHMRC) guidelines for guidelines.
- Commitment to inclusivity, transparency, and making an impact on outcomes for those living with MND.
Guideline Questions
Our guideline development is an ongoing process. Here, you can see what we are currently working on with the first iteration of guideline questions. We will also provide access to the full set of questions we aim to address in future updates.
Evidence and Gap Maps
An Evidence and Gap Map (EGM) shows where research evidence exists and where there are gaps. To support the development of the Australian MND Guideline, we mapped evidence informing the care and management of people living with MND, including evidence relating to their carers, asymptomatic genetic carriers, family, friends and healthcare professionals.
The maps below summarise the available evidence on pharmacological interventions, technology and equipment, medical and clinical, models of care and support and symptom management.